Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 7:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 110 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Rosiglitazone Clear all
Completed Phase 4 Interventional

Pioglitazone Study of Triglyceride Changes in Subjects With Type 2 Diabetes After Conversion From Rosiglitazone.

NCT00672919
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Pioglitazone
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 70 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
51
States / cities
Birmingham, Alabama • Tucson, Arizona • Bellflower, California + 48 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Oct 17, 2026, 7:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drug-Drug Interaction Study Between Quinine Sulfate and Rosiglitazone

NCT00785213
View directory record Official record
Conditions
Healthy
Interventions
Rosiglitazone 4 mg Tablets, Quinine Sulfate 324 mg Capsules
Drug
Lead sponsor
Mutual Pharmaceutical Company, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
East Grand Forks, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Oct 17, 2026, 7:18 AM EDT
Completed Phase 1 Interventional Results available

A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists

NCT01209143
View directory record Official record
Conditions
Solid Cancers
Interventions
Vismodegib, Rosiglitazone, Norethindrone/ethinyl estradiol
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
3
States / cities
Stanford, California • Detroit, Michigan • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2015 · Synced Oct 17, 2026, 7:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Diet, Exercise and/or Rosiglitazone for HIV-Associated Insulin Resistance

NCT00264251
View directory record Official record
Conditions
HIV Infections, Insulin Resistance, Obesity
Interventions
Weight loss through diet and exercise, Rosiglitazone insulin sensitizing agent
Behavioral · Drug
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
20 Years to 60 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 29, 2007 · Synced Oct 17, 2026, 7:18 AM EDT
Completed Phase 1 Interventional

Endothelial Dysfunction as a Risk Factor in HIV Study

NCT00039663
View directory record Official record
Conditions
HIV Infections
Interventions
Pravastatin, Gemfibrozil, Rosiglitazone
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 17, 2026, 7:18 AM EDT
Completed Phase 3 Interventional Results available

Effects of Colesevelam HCl, Rosiglitazone, Sitagliptin on Control of Blood Glucose and Lipids in Type 2 Diabetes Patients Whose Blood Glucose Isn't Completely Controlled With Metformin

NCT00484419
View directory record Official record
Conditions
Type 2 Diabetes, Hyperlipidemia
Interventions
Colesevelam HCl, rosiglitazone maleate, sitagliptin phosphate
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 80 Years
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
20
States / cities
La Mesa, California • Los Angeles, California • Los Gatos, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2016 · Synced Oct 17, 2026, 7:18 AM EDT
Recruiting Phase 2 Interventional

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

NCT04114136
View directory record Official record
Conditions
Melanoma, NSCLC, Hepatocellular Carcinoma, Urothelial Cancer, Gastric Adenocarcinoma, HNSCC, Esophageal Adenocarcinoma, Microsatellite Instability-High Solid Malignant Tumor
Interventions
Nivolumab or Pembrolizumab (dependent upon approved indication), Metformin, Rosiglitazone
Drug
Lead sponsor
Dan Zandberg
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2032
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 17, 2026, 7:18 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effect of Rosiglitazone on the Vascular Biology of Human Fat Tissue

NCT01150981
View directory record Official record
Conditions
Metabolic Syndrome, Insulin Resistance
Interventions
Rosiglitazone, Placebo
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 26, 2012 · Synced Oct 17, 2026, 7:18 AM EDT
Completed Phase 3 Interventional

Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes

NCT00333151
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, rosiglitazone, metformin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 80 Years
Enrollment
576 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
71
States / cities
Goodyear, Arizona • Colton, California • Concord, California + 59 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2017 · Synced Oct 17, 2026, 7:18 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

QTc Study of Rosi XR in Healthy Volunteers

NCT00884533
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Rosi XR, Placebo, Moxifloxacin
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 17, 2015 · Synced Oct 17, 2026, 7:18 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of Rosiglitazone/Metformin Therapy vs Rosiglitazone and Metformin in Type 2 Diabetes Subjects

NCT00499707
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
rosiglitazone maleate/metformin hydrochloride
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 70 Years
Enrollment
453 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
48
States / cities
Anniston, Alabama • Chandler, Arizona • Phoenix, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Oct 17, 2026, 7:18 AM EDT
Terminated Phase 3 Interventional

Ppar-Gamma EliminAtes Restenosis Longevity Study: PEARLS

NCT00465296
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
rosiglitazone
Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 22, 2008 · Synced Oct 17, 2026, 7:18 AM EDT
Completed Phase 4 Interventional Results available

Rosiglitazone for Clozapine Induced Glucose Metabolism Impairment

NCT00337350
View directory record Official record
Conditions
Schizophrenia
Interventions
rosiglitazone, placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 8, 2015 · Synced Oct 17, 2026, 7:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of VX-770 on Midazolam and Rosiglitazone and the Effect of Fluconazole on VX-770

NCT01060566
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-770
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Apr 16, 2010 · Synced Oct 17, 2026, 7:18 AM EDT
Completed Phase 2 Interventional Results available

Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial

NCT00814255
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis
Interventions
Adalimumab, Lisinopril, losartan, and atorvastatin, galactose
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
1 Year to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
17
States / cities
Miami, Florida • Atlanta, Georgia • Kansas City, Kansas + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2016 · Synced Oct 17, 2026, 7:18 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance

NCT00130286
View directory record Official record
Conditions
HIV-Associated Lipodystrophy Syndrome, Insulin Resistance, HIV Infections, Metabolic Syndrome X, Body Weight Changes
Interventions
Rosiglitazone, Recombinant human growth hormone + rosiglitazone
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 65 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
4
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Oct 17, 2026, 7:18 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

A Study for Pre-diabetic Patients With Cholesterol Lowering Drugs

NCT00831129
View directory record Official record
Conditions
Pre-diabetes
Interventions
Rosiglitazone, Placebo Rosiglitazone, Simvastatin
Drug
Lead sponsor
University of Chicago
Other
Eligibility
21 Years to 75 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 10, 2017 · Synced Oct 17, 2026, 7:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparing Tricor, Avandia, or Weight Loss to Lower Cardiovascular Risk Factors in People With High Triglycerides.

NCT00186537
View directory record Official record
Conditions
Insulin Resistance, Hypertriglyceridemia
Interventions
Rosiglitazone, Fenofibrate, Weight Loss
Drug · Behavioral
Lead sponsor
Stanford University
Other
Eligibility
30 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2008
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 17, 2026, 7:18 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Vildagliptin vs. Thiazolidinedione as add-on Therapy to Metformin in Patients With Type 2 Diabetes Not Controlled With Metformin Alone

NCT00396227
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
vildagliptin, thiazolidinedione (TZD)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
2,665 participants
Timeline
Started 2006
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 18, 2016 · Synced Oct 17, 2026, 7:18 AM EDT
Completed No phase listed Observational

Markers and Mechanisms of Vascular Disease in Type II Diabetes

NCT00256646
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Rosiglitazone
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
40 Years and older
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
16
States / cities
Phoenix, Arizona • Tucson, Arizona • Fresno, California + 13 more
Source: ClinicalTrials.gov public record
Updated May 23, 2014 · Synced Oct 17, 2026, 7:18 AM EDT
Completed Phase 4 Interventional

Effect of Thiazolidinedione Treatment Vascular Risk Markers

NCT00571506
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Vascular Diseases
Interventions
Rosiglitazone, Pioglitazone
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
40 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Dec 9, 2009 · Synced Oct 17, 2026, 7:18 AM EDT
Completed Not applicable Interventional

Metformin and Rosiglitazone, Alone or in Combination, in HIV-Infected Patients With Insulin and Fat Abnormalities

NCT00015691
View directory record Official record
Conditions
HIV Infections, Lipodystrophy, Hyperinsulinemia
Interventions
Metformin hydrochloride, Rosiglitazone maleate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
34
States / cities
Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2013 · Synced Oct 17, 2026, 7:18 AM EDT
Terminated Phase 4 Interventional Results available

Pioglitazone to Treat Fatty Liver in Patients With HIV and Hepatitis C Infections

NCT00742326
View directory record Official record
Conditions
HIV, Hepatitis C, Liver Disease, Fatty Liver, Steatosis
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 9, 2016 · Synced Oct 17, 2026, 7:18 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Rosiglitazone to Treat Patients With Heart Failure and Glucose Intolerance or Type II Diabetes

NCT00064727
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Avandia (Rosiglitazone), Avanclia (Rosiqlitazone)
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
22 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2007
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 17, 2026, 7:18 AM EDT